Genetic, Environmental, and Nuclear Factors Governing Genomic Rearrangements
- PMID: 31900904
- DOI: 10.1007/978-3-030-32656-2_3
Genetic, Environmental, and Nuclear Factors Governing Genomic Rearrangements
Abstract
Studies employing whole genome and exome sequencing have revealed two remarkable features of prostate cancer (PCa)-the overall low mutation rates, and high rates of genomic rearrangements resulting in recurrent gene fusions. Genomic rearrangements involving the ETS transcription factor family genes are early driver events in PCa. These rearrangements typically involve the fusion of androgen-regulated transcriptionally active genes with the ETS genes (ERG, ETV1, ETV4 and ETV5), resulting in over-expression of fusion genes. The most prevalent ETS gene rearrangement, which is observed in >50% of PCa, involves the fusion of the androgen receptor (AR) target gene, TMPRSS2, with the ERG proto-oncogene, resulting in the formation of the TMPRSS2-ERG gene fusion. In this chapter, we consider the multitude of factors that influence the formation of recurrent genomic rearrangements in PCa. Understanding the mechanistic basis of gene fusion formation will shed light on unique features of PCa etiology and should impact several aspects of clinical disease management, ranging from prevention and early diagnosis to therapeutic targeting.
Similar articles
-
[Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):669-73. Zhonghua Yi Xue Za Zhi. 2008. PMID: 18642766 Chinese.
-
Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.Neoplasia. 2013 Jul;15(7):720-6. doi: 10.1593/neo.13232. Neoplasia. 2013. PMID: 23814484 Free PMC article.
-
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.Nature. 2007 Aug 2;448(7153):595-9. doi: 10.1038/nature06024. Nature. 2007. PMID: 17671502
-
ETS gene fusions in prostate cancer.Nat Rev Urol. 2009 Aug;6(8):429-39. doi: 10.1038/nrurol.2009.127. Nat Rev Urol. 2009. PMID: 19657377 Review.
-
ETS fusion genes in prostate cancer.Endocr Relat Cancer. 2014 May 6;21(3):R143-52. doi: 10.1530/ERC-13-0390. Print 2014 Jun. Endocr Relat Cancer. 2014. PMID: 24659477 Review.
Cited by
-
Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH).Prostate. 2022 Jun;82(8):933-941. doi: 10.1002/pros.24339. Epub 2022 Mar 24. Prostate. 2022. PMID: 35322894 Free PMC article.
-
Targeting radioresistance and replication fork stability in prostate cancer.JCI Insight. 2022 May 9;7(9):e152955. doi: 10.1172/jci.insight.152955. JCI Insight. 2022. PMID: 35349486 Free PMC article.
-
Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance.Front Oncol. 2025 Feb 11;15:1542811. doi: 10.3389/fonc.2025.1542811. eCollection 2025. Front Oncol. 2025. PMID: 40008000 Free PMC article. Review.
-
Fusion Genes in Prostate Cancer: A Comparison in Men of African and European Descent.Biology (Basel). 2022 Apr 20;11(5):625. doi: 10.3390/biology11050625. Biology (Basel). 2022. PMID: 35625354 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials